A Dye for the Detection of Cancer of the Tongue and Mouth

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Oral Squamous Cell Carcinoma (OSCC)
Interventions
DRUG

Olaparib

For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Consent Only), Harrison

11553

Memorial Sloan Kettering Nassau (Consent only), Rockville Centre

11725

Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack

07920

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Consent only), Middletown

07645

Memorial Sloan Kettering Bergen (Consent only), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03085147 - A Dye for the Detection of Cancer of the Tongue and Mouth | Biotech Hunter | Biotech Hunter